Log In

New? Register Here

Elan Corporation plc ADR

Treasury Building Lower Grand Canal Street, Dubl

  • Main Phone: (531) 709-4000
  • Fax Number: (531) 709-4700
  • Date Founded: N/A
  • Employees: N/A
  • Testimonials: None Provided
  • Endorsements: None Provided
  • Announcements: 0


Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan s business focuses on neurodegenerative diseases, such as Alzheimer s disease and Parkinson s disease; autoimmune diseases, including MS and Crohn s disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn s disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.


Not provided at this time


Not provided at this time


There are no company announcements at this time.

Company's Strengths and Specialties

There is no information provided at this time.